Siemers Eric 4

Accession 0001628280-26-002959

CIK 0001576885other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 6:31 PM ET

Size

7.3 KB

Accession

0001628280-26-002959

AI-generated summary of this filing

Updated Jan 21, 2026

Acumen (ABOS) CMO Eric Siemers Receives RSU & Option Awards

What Happened

Eric Siemers, Chief Medical Officer of Acumen Pharmaceuticals (ABOS), received equity awards on 2026-01-16: 99,133 restricted stock units (RSUs) and 148,700 derivative/option-related shares. Both grants were issued at $0.00 (no cash paid) as reported on a Form 4 filed 2026-01-21. These are grants/awards, not open-market purchases or sales.

Key Details

Transaction date: 2026-01-16; Form 4 filed: 2026-01-21 (filed on the second business day after the grant; appears timely).
Grant values reported at $0.00 per share (typical for RSU/option grants); total cash outlay = $0 at grant.
Vesting: the 99,133 RSUs vest in three equal annual installments starting one year after the grant date (Footnote F1). The 148,700 derivative/option shares vest in 48 equal monthly installments over four years (Footnote F2).
Shares owned following the reported transactions: not specified in the filing.
Transaction code: A = Award/Grant. No sale, purchase (P/S), or tax-withholding (F) entry reported in this filing.

Context

RSUs represent a contingent right to receive shares upon vesting; they do not provide immediate stock ownership until each tranche vests. The derivative/option-style award will vest monthly, meaning shares become exercisable/owned over time if the reporting person remains in service.
Awards are common compensation tools for executives and do not, by themselves, indicate a buy or sell signal; they reflect company compensation decisions rather than an insider trading preference.

Form 4

Period: 2026-01-16

Chief Medical Officer

Transactions

Award
Common Stock
[F1]
2026-01-16+99,133→ 258,597 total
Award
Employee Stock Option (right to buy)
[F2]
2026-01-16+148,700→ 148,700 total
Exercise: $1.89Exp: 2036-01-16→ Common Stock (148,700 underlying)

Footnotes (2)

[F1]Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
[F2]The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Signature

/s/ Derek Meisner, Attorney-in-Fact|2026-01-21

1 file

Acumen Pharmaceuticals, Inc.

CIK 0001576885

Entity typeother